Vennin P, Hecquet B, Poissonnier B, Fournier C, Lequint A, Delobelle A, Demaille M C
Centre Oscar Lambret, Lille, France.
Gynecol Oncol. 1989 Feb;32(2):180-3. doi: 10.1016/s0090-8258(89)80030-7.
In order to define the influence of intraarterial administration of cis-platinum in tumors of the cervix, a preliminary crossover study was performed to measure and compare the intratumoral concentrations (ITC) of platinum obtained respectively after intravenous (iv) and intraarterial (ia) (both bilateral hypogastric arteries) injection. The results in nine patients demonstrate that higher (P = 0.05) intratumoral concentrations are obtained after intraarterial injection of cis-platinum: 10; 3.7-23.7 ng Pt/mg of dry tissue after ia (median; range) 6.9; 4.1-23.6 ng Pt/mg tissue after iv. This difference is probably too small to be of clinical significance and a comparative clinical trial does not seem to be warranted. The results also show a large intersubject variation in intratumoral platinum concentration which are reproducible in patients whatever route of administration is used. Thus the observed differences in ITC are more related to the variability of the tumor properties than to the route of administration.
为了确定动脉内给予顺铂对宫颈癌肿瘤的影响，进行了一项初步交叉研究，以测量和比较分别经静脉注射（iv）和动脉内注射（ia）（双侧腹下动脉）后获得的肿瘤内铂浓度（ITC）。9名患者的结果表明，动脉内注射顺铂后肿瘤内浓度更高（P = 0.05）：动脉内注射后为10；3.7 - 23.7 ng铂/毫克干组织（中位数；范围），静脉注射后为6.9；4.1 - 23.6 ng铂/毫克组织。这种差异可能太小，无临床意义，似乎没有必要进行对比临床试验。结果还显示，无论采用何种给药途径，患者肿瘤内铂浓度在个体间存在很大差异，且具有可重复性。因此，观察到的ITC差异更多地与肿瘤特性的变异性有关，而非给药途径。
